The RNAi for Functional Genomics Screening will cover the latest in the use of RNA interference (RNAi) screens for identifying and validating drug targets and exploring unknown cellular pathways. It will cover everything from assay design to data analysis for the use of in vitro and in vivo siRNA (small interfering RNA) and shRNA (short hairpin RNA) screens. There is growing interest in combining RNAi screens with gene editing, chemical genomics, overexpression studies and phenotypic screens, which will all be discussed here. Screening experts from industry and academia will share their experiences leveraging the utility of these diverse screening platforms for a wide range of applications.
Harnessing High Throughput RNAi for Target Identification Utilizing 3D cell Culture Models
Geoffrey Bartholomeusz, Ph.D., Associate Professor and Director, siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center
Development of Physiologically Relevant Assay Platforms to Probe Various Disease Pathologies
Madhu Lal-Nag, Ph.D., Team Leader, RNAi Screening, National Center for Advancing Translational Sciences, National Institutes of Health
Talk Title to be Announced
Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc.
Identifying Regulatory Interactions Among Genes Linked to Alzheimer’s Disease
Michael Ollmann, Ph.D., Principal Scientist, Genome Analysis Unit, Amgen Inc.
RNAi for Rare Disease Drug Discovery; Signal or Noise?
Christopher Gibson, Ph.D., Co-Founder and CEO, Recursion Pharmaceuticals
Development and Application of CARD, a Comprehensive Integrated Web-Based Platform for Analysis of RNAi Screening Data
Iain Fraser, Ph.D., Investigator, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health
3D Phenotypic Screening for Target Identification and Drug Discovery
Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
The Path From Arrayed RNAi to Arrayed CRISPR Screens: Lessons Learned and Challenges
Eugen Buehler, Ph.D., Group Leader, Informatics, National Center for Advancing Translational Sciences, National Institutes of Health
Pooled shRNA, Arrayed siRNA and CRISPR-Cas9: Three Essential Tools Towards Understanding Gene Function in Cancer and Disease Biology
Ralph Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center
Parallel shRNA and CRISPR/Cas9 Screens Reveal Biology of Stress Pathways and Identify Novel Drug Targets
Michael Bassik, Ph.D., Assistant Professor, Department of Genetics, Stanford University
Screening the Kinome: Lessons From Using Functional Screens in Glioblastoma Stem Cells
Brent Cochran, Ph.D., Professor, Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine
For more details on the conference, please contact:
Tanuja Koppal, Ph.D.
Cambridge Healthtech Institute
For partnering and sponsorship information, please contact:
Sr. Business Development Manager
Cambridge Healthtech Institute
T: (+1) 781-972-5483